Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Vanda Pharmaceuticals (VNDA) Accumulated Depreciation & Amortization (2016 - 2025)

Vanda Pharmaceuticals' Accumulated Depreciation & Amortization history spans 15 years, with the latest figure at $12.6 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 9.07% to $12.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.6 million, a 9.07% increase, with the full-year FY2025 number at $12.6 million, up 9.07% from a year prior.
  • Accumulated Depreciation & Amortization hit $12.6 million in Q4 2025 for Vanda Pharmaceuticals, up from $11.6 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for VNDA hit a ceiling of $12.6 million in Q4 2025 and a floor of $9.4 million in Q4 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $11.0 million across 5 years, with a median of $11.2 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 16.8% in 2021 and later increased 3.45% in 2024.
  • Tracing VNDA's Accumulated Depreciation & Amortization over 5 years: stood at $9.4 million in 2021, then rose by 11.11% to $10.4 million in 2022, then rose by 7.31% to $11.2 million in 2023, then rose by 3.45% to $11.6 million in 2024, then increased by 9.07% to $12.6 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for VNDA at $12.6 million in Q4 2025, $11.6 million in Q4 2024, and $11.2 million in Q4 2023.